CN Patent

CN120053445A — 用于治疗hiv的衣壳抑制剂

Assigned to Gilead Sciences Inc · Expires 2025-05-30 · 1y expired

What this patent protects

本发明涉及式(Ia)或式(Ib)的化合物或其药学上可接受的盐，其用于治疗患有多重耐药性HIV感染的经历大量治疗的患者的HIV感染。

USPTO Abstract

本发明涉及式(Ia)或式(Ib)的化合物或其药学上可接受的盐，其用于治疗患有多重耐药性HIV感染的经历大量治疗的患者的HIV感染。

Drugs covered by this patent

lenacapavir-sodium (LENACAPAVIR SODIUM)

Patent Metadata

Patent number: CN120053445A
Jurisdiction: CN
Classification: —
Expires: 2025-05-30
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.